Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Clinical trial NCT03739606 · WITHDRAWN

Trial details

NCT number: NCT03739606
Sponsor: City of Hope Medical Center
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Biphenotypic Leukemia Acute Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hairy Cell Leukemia Interleukin-3 Receptor Subunit Alpha Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Refractory Acute Lymphoblastic Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Start date: 2020-10-20
Primary completion: 2020-10-20
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.